Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 N701K |
| Therapy | FF-10101 |
| Indication/Tumor Type | hematologic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 N701K | hematologic cancer | sensitive | FF-10101 | Preclinical - Cell culture | Actionable | In a preclinical study, FF-10101 treatment inhibited viability of cells expressing a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132). | 37815132 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37815132) | The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. | Full reference... |